Casi Pharmaceuticals Stock Executives

CASI
 Stock
  

USD 1.99  0.08  4.19%   

Casi Pharmaceuticals employes about 176 people. The company is managed by 14 executives with total tenure of roughly 101 years, averaging almost 7.0 years of service per executive having 12.57 employees per reported executive. Examination of Casi Pharmaceuticals management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Casi Pharmaceuticals future performance.
Continue to Trending Equities.
  
  Ken Ren  CEO
CEO
  WeiWu He  Chairman
Chairman of the Board
  Wei Zhang  President
President of CASI China

Casi Pharmaceuticals Return on Sales

(1.31)

Casi Pharmaceuticals Management Team Effectiveness

Casi Pharmaceuticals has return on total asset (ROA) of (15.8) % which means that it has lost $15.8 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (30.23) %, meaning that it created substantial loss on money invested by shareholders. Casi Pharmaceuticals management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -54.1. The current Return on Average Assets is estimated to decrease to -29.73. Casi Pharmaceuticals Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 76.33 Million. The current Goodwill and Intangible Assets is estimated to increase to about 12.5 M, while Asset Turnover is projected to decrease to 0.21.
The current Weighted Average Shares is estimated to increase to about 14.7 M. The current Weighted Average Shares Diluted is estimated to increase to about 14.7 M

Casi Pharmaceuticals Workforce Comparison

Casi Pharmaceuticals is rated second in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 322,991. Casi Pharmaceuticals adds roughly 176 in number of employees claiming only tiny portion of stocks in Biotechnology industry.

Casi Pharmaceuticals Profit Margins

The company has Profit Margin (PM) of (91.97) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (95.4) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.95.

Casi Pharmaceuticals Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Casi Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Casi Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Casi Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Casi Pharmaceuticals Benchmark Summation

The output start index for this execution was fifty-nine with a total number of output elements of two. The Lowest value over a specified period line plots minimum value of Casi Pharmaceuticals price series.
.

Casi Pharmaceuticals Notable Stakeholders

A Casi Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Casi Pharmaceuticals often face trade-offs trying to please all of them. Casi Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Casi Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ken Ren - CEOProfile
WeiWu He - Chairman of the BoardProfile
Wei Zhang - President of CASI ChinaProfile
Sara Capitelli - Vice President - Finance, Principal Accounting OfficerProfile
George Chi - CFOProfile
Cynthia Hu - COO, General Counsel, SecretaryProfile
Quan Zhou - Independent DirectorProfile
James Huang - Independent DirectorProfile
Franklin Salisbury - Independent DirectorProfile
Tak Mak - DirectorProfile
Alexander Wu - Independent DirectorProfile
Rajesh Shrotriya - DirectorProfile
Alexander Zukiwski - Chief Medical OfficerProfile
Rong Chen - Chief Medical OfficerProfile

About Casi Pharmaceuticals Management Performance

The success or failure of an entity such as Casi Pharmaceuticals often depends on how effective the management is. Casi Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Casi Pharmaceuticals management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Casi Pharmaceuticals management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2022
Return on Investment(50.14) (54.10) 
Return on Average Assets(27.56) (29.73) 
Return on Average Equity(44.15) (47.64) 
Return on Invested Capital(0.57) (0.58) 
Return on Sales(1.22) (1.31) 
The data published in Casi Pharmaceuticals' official financial statements usually reflect Casi Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Casi Pharmaceuticals. For example, before you start analyzing numbers published by Casi Pharmaceuticals accountants, it's critical to develop an understanding of what Casi Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Casi Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Casi Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Casi Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Casi Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Casi Pharmaceuticals' management to manipulate its earnings.

Casi Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Casi Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Casi Pharmaceuticals within its industry.

Casi Pharmaceuticals Manpower Efficiency

Return on Casi Pharmaceuticals Manpower

Revenue Per Employee154.9 K
Revenue Per Executive2.5 M
Net Loss Per Employee224.7 K
Net Loss Per Executive2.3 M
Working Capital Per Employee77.5 K
Working Capital Per Executive973.9 K
Today, most investors in Casi Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Casi Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Casi Pharmaceuticals per employee as a starting point in their analysis.

Per Employee

Casi Pharmaceuticals Per Employee Growth Over Time

Net Income Per Employee

(224,703)

Casi Pharmaceuticals Net Income Per Employee is most likely to increase significantly in the upcoming years. The last year's value of Net Income Per Employee was reported at (208,261)

Revenue Per Employee

154,858

Casi Pharmaceuticals Revenue Per Employee is most likely to decrease significantly in the upcoming years. The last year's value of Revenue Per Employee was reported at 171,409
Continue to Trending Equities. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for analysis

When running Casi Pharmaceuticals price analysis, check to measure Casi Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Casi Pharmaceuticals is operating at the current time. Most of Casi Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Casi Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Casi Pharmaceuticals' price. Additionally, you may evaluate how the addition of Casi Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Is Casi Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Casi Pharmaceuticals. If investors know Casi Pharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Casi Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
26.3 M
Quarterly Revenue Growth YOY
0.26
Return On Assets
(0.15) 
Return On Equity
(0.27) 
The market value of Casi Pharmaceuticals is measured differently than its book value, which is the value of Casi Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Casi Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Casi Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Casi Pharmaceuticals' market value can be influenced by many factors that don't directly affect Casi Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Casi Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Casi Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Casi Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.